NCT05550207CompletedPhase 3
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
An Open-Label, Multiple-Dose Evaluation of the Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor
Source: ClinicalTrials.gov · Last updated 2 Dec 2025
Brief summary (registry, in English)
This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 19 Sept 2022
- Start date
- 31 Aug 2022
- Primary completion date
- 27 Nov 2024
- Lead sponsor
- Axsome Therapeutics, Inc.
- Diseases
- Migraine
- NCT number
- NCT05550207
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 100
- From 31 Aug 2022 to the primary completion date, 27 Nov 2024
- 31 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has previously received any investigational drug or device or investigational therapy within 30 days before Screening
Other
- Pregnant, breastfeeding, or planning to become pregnant during the study
Who the study is looking for
- Has an established diagnosis of migraine with or without aura
- Has experienced an inadequate response to oral CGRP inhibitors for the acute treatment of migraine
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (31)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.